New Injectable Agents for the Treatment of Type 2 Diabetes Part 2—Glucagon-Like Peptide-1 (GLP-1) Agonists - 29/10/18
![](/templates/common/images/mail.png)
![](/templates/common/images/mail.png)
Pharmacology Series Editor, Rhonda M. Cooper-DeHoff, PharmD, MS
Abstract |
The US Food and Drug Administration has recently approved several new glucagon-like peptide-1 (GLP-1) agonists alone and in combination with various insulin products. The second of 2 articles in a series, this review will describe the potential advantages and disadvantages of the GLP-1 agonist class of products.
Le texte complet de cet article est disponible en PDF.Keywords : GLP-1 combination products, Glucagon like peptide-1 (GLP-1) agonist, Type 2 diabetes
Plan
Funding: None. |
|
Conflict of Interest: None. |
|
Authorship: All authors had access to data and a role in writing this manuscript. |
Vol 131 - N° 11
P. 1304-1306 - novembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?